报价延迟最少15分钟:2026/09/03 18:15 EDT
盘后时段
|
||||
|
16.12 
|
|
|
常规时段 (已结束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
16.12
|
|
|
| 价值评估 |
|
盈利(现时/预测)
2.28/1.97
|
|
企业价值
2.22B
|
| 资产负债 |
|
每股账面净值
4.62
|
| 现金流量 |
|
现金流量率
0.08
|
| 损益表 |
|
收益
318.00K
|
|
每股收益
2.13
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases. |
